Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

BACKGROUND: Sym004 is a mixture of two monoclonal antibodies (mAbs), futuximab and modotuximab, targeting non-overlapping epitopes on the epidermal growth factor receptor (EGFR). Previous studies have shown that Sym004 is more efficient at inducing internalization and degradation of EGFR than indivi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Neurooncol
Egile Nagusiak: Keir, Stephen T., Chandramohan, Vidyalakshmi, Hemphill, Carlee D., Grandal, Michael M., Melander, Maria Carlsen, Pedersen, Mikkel W., Horak, Ivan D., Kragh, Michael, Desjardins, Annick, Friedman, Henry S., Bigner, Darell D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2018
Gaiak:
Laboratory Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5999169/
https://ncbi.nlm.nih.gov/pubmed/29564747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2832-6
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak